Claims

1. A solid preparation having a phase wherein an insulin sensitizer and an active ingredient (except insulin sensitizers) are uniformly dispersed, and a hardness of 100 to 400N.

2. The solid preparation of claim 1, wherein the active ingredient is a biguanide.

3. The solid preparation of claim 2, wherein the biguanide is metformin hydrochloride.

4. A solid preparation having a phase wherein an insulin sensitizer and an active ingredient (except insulin sensitizers) having a ratio of median size thereof to the median size of said insulin sensitizer of 0.5 to 15 are uniformly dispersed.

5. The solid preparation of claim 4, wherein the active ingredient is a biguanide.

6. The solid preparation of claim 5, wherein the biguanide is metformin hydrochloride.

7. A solid preparation having a phase wherein an insulin sensitizer and an active ingredient (except insulin sensitizers) are uniformly dispersed, and a coefficient of variation of the insulin sensitizer content of not more than 6%.

8. The solid preparation of claim 7, wherein the active ingredient is a biguanide.

9. The solid preparation of claim 8, wherein the biguanide is metformin hydrochloride.

10. A solid preparation having a phase wherein an insulin sensitizer and an active ingredient (except insulin sensitizers) are uniformly dispersed, which elutes out not less than 70% of the insulin sensitizer at 30 min after in a dissolution test according to a Paddle Method using a hydrochloric acid-potassium chloride buffer (pH 2.0) as a test solution at 37°C, 50 rpm.

11. The solid preparation of claim 10, wherein the active ingredient is a biguanide.

12. The solid preparation of claim 11, wherein the biguanide is metformin hydrochloride.

13. A solid preparation having a phase wherein pioglitazone hydrochloride and metformin hydrochloride having a ratio of median size thereof to the median size of said pioglitazone hydrochloride of 0.5 to 15 are uniformly dispersed.

14. The solid preparation of claim 13, which is film-coated.